Logo

Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Metastatic Cervical Cancer

Share this

Seagen and Genmab's Tivdak (tisotumab vedotin-tftv) Receive the US FDA's Accelerated Approval for the Treatment of Recurrent or Metastatic Cervical Cancer

Shots:

  • The approval is based on the P-II innovaTV 204 clinical trials evaluating tisotumab vedotin in 101 patients with r/mCC who had received no more than two prior systemic regimens in the recurrent or metastatic setting- including one prior Pt-based CT regimen
  • The results showed an ORR (24%) as assessed by IRC using RECIST v1.1 criteria- m-DoR (8.3mos.)
  • Tivdak is the first approved ADC that directed to TF and Seagen’s ADC technology that utilizes a protease-cleavable linker & covalently attaches the microtubule-disrupting agent MMAE to Ab. The P-III innovaTV 301clinical trial of Tivdak is underway that is intended to support global registrations

| Ref: Business wire Image: reuter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions